A New and Improved Contrast Agent for Multiparametric MRI
Skip the contrast agent, and a prostate MRI gets faster and cheaper, but it loses the one signal that makes cancer impossible to miss: abnormal blood flow. That trade-off is why the third MRI sequence matters, and why a newly approved low-dose contrast agent is worth watching. It offers the same vascular proof with a fraction of the gadolinium. keep reading
